Precise results in 75 minutes: increased Covid-19 laboratory testing throughput and cost savings with innovative Rapid PCR Detection Kit

(PresseBox) ( Heidelberg/Germany, )
Compike develops and sells innovative tracking & tracing solutions based on AutoID and sensor technologies for a wide range of industries and has decades of knowledge and experience from its founders, employees and partners in the areas of IoT, automated identification, track & trace and microbiology.

Since the beginning of the corona pandemic, Compike has been marketing a modular solution portfolio globally consisting of the following components:
  • a so-called "social distance tracker" for seamless contact tracking of people (turnkey solution for companies and, for example, the tourism industry consisting of hardware and software)
  • Covid-19 Rapid PCR Detection Kit (in cooperation with our technology partner Genmark Sağlık Urunleri Ltd.)
  • Covid-19 Antibody Rapid Test (in cooperation with our technology partner Oncosem)
Compike and its technology partners are convinced that, especially through the potential use of the Rapid PCR tests, better protection of citizens and great advantages can be achieved by saving time and money in mass testings. With the Rapid PCR test, national PCR laboratories can carry out significantly more tests per day without sacrificing the sensitivity and quality of the analysis and at the same time saving costs. The Rapid PCR Detection Kit provides precise results with a one-step enzyme system and utilizes the direct sample qRT-PCR method. There is no need for an additional RNA extraction step and no further addition necessary. The Rapid Detection Kit meets the recommended and required sensitivity of WHO and CDC analogous to regular RT-PCR tests, but in a much shorter time with reliable results within 75 minutes (target genes: ORF1ab and N genes from 2019-nCoV).

Due to the fact that there is no separate extraction needed, the s avings in accessories and consumables sum up to appro ximately 3 to 5 Euros per test compared to other PCR kits ( tube, etc.) O ther big advantage s are l ess work for laboratory staff, the user friendly and efficient handling and less risk of contamination

The Rapid Detection Kit has been validated with most of the common PCR instruments This largely device independency is another great factor for savings because laboratories typically don´t need to purchase new hardware for performing the t ests. In addition, the labs can achieve a dramatically higher laboratory throughput which means more tests per day with a very high sensitivity Ex ample: the Rapid Covid 19 PCR Detection K it is validated on mainstream RT PCR instruments including Biorad CF X 384 which enables laboratories to process and generate results for up to 6 000 patients within 24 h ours with one single PCR instrument e.g. suitable for mass quantity screenings like airports tourism, exhibitions or sports events

The Covid 19 Rapid PCR Detection Kit comes with a CE IVD marking, numerous reference customers, clinical laboratory validations and an EU registration ("EU COVID 19 In Vitro Diagnostic Devices and Test Methods Database") The FDA approval is initiated as well and should be available in short term.

Compike is the exclusive sales channel for the components and test kits listed above in Austria, Brazil, Germany, Mexico, Philippines, Romania, USA and various other countries. More details can be found on the Compike website: or requested via email
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an